63 results about "Sigma ligands" patented technology

The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptors. These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by ischemic stroke, diabetic peripheral neuropathy, cancer therapy induced neuropathy, multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, spinal cord injury, Huntington's disease or Parkinson's disease. In other methods, the sigma receptor ligands are administered after stroke to facilitate functional recovery. The administration of the sigma receptor ligands effects faster functional recovery.

A new class of bridged bis(tetrahydro-indenyl)metallocenes of formula (I),wherein M is Zr or Hf; X are monoanionic sigma ligands; (ZR1i)j is a divalent group bridging the two tetrahydro-indenyl residues; R2 and R3 are halogen, alkyl, cycloalkyl, aryl, alklyaryl or arylalkyl radicals; p is 0-3; i is 1 or 2; j is 1-4; m is 1-2; and n is 0-8. Furthermore, catalysts systems for olefin polymerization containing them are described.

The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat opioid-induced hyperalgesia (OIH) associated to opioid therapy.

The invention refers to the use of a sigma ligand, particularly a sigma ligand of formulae (I), (II) or (III) to prevent and/or treat acute and chronic pain developed as a consequence of surgery, especially superficial and/or deep pain secondary to surgical tissue injury, and peripheral neuropathic pain, neuralgia, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuritis or neuropathy secondary to surgical procedure.

The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat pain associated to bone cancer.

The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferably AGY-94806, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by multiple sclerosis. In other methods, the sigma receptor ligands are administered after MS to facilitate functional recovery. The administration of the sigma receptor ligands causes faster functional recovery.

A solid, particulate catalyst comprising: (i) a complex of Formula (I), wherein M is zirconium or hafnium; each X is a sigma ligand; L is a divalent bridge selected from -R'2C-, -R'2C-CR'2-, -R'2Si-, -R'2Si-SiR'2-, -R'2Ge-, wherein each R' is independently a hydrogen atom, C1-C20-alkyl, tri(C1-C20-alkyl)silyl, C6-C20-aryl, C7-C20-arylalkyl or C7-C20-alkylaryl; each R1 independently is a linear or branched C1-C20 hydrocarbyl radical optionally containing one or more heteroatoms from groups 14-16; T1 and T4, which can be the same or different, are an OR<2>, a SR<2>, CH(R<18>)2, CH2R<18>, aryl or heteroaryl group; each R<2>, which can be the same or different, is a C1-C20 hydrocarbyl radical; each R<18>, which can be the same or different, is a C1-C20 hydrocarbyl radical or two R<18> groups together with the carbon atom to which they are attached may form a cyclic C4-C20 hydrocarbyl group; T2 and T3, which may be the same or different, are a C(R<18>)3 group; W1 and W2, which may be the same or different, are a 5 or 6 membered aryl or heteroaryl ring wherein each atom of said ring is optionally substituted with an R<5> group; each R<5>, which can be the same or different, is a C1-C20 hydrocarbyl radical optionally containing one or more heteroatoms belonging to groups 14-16; and optionally two adjacent R<5> groups taken together can form a further mono or multicyclic ring condensed to W1 or W2, optionally substituted by one or two groups R5; and (ii) a cocatalyst.

The invention refers to the use of a sigma ligand of formula (I) to prevent or treat pain induced by a chemotherapeutic agent, especially pain induced by taxanes, vinca alkaloids or platinum-containing chemotherapeutic drugs.

Catalyst system for producing ethylene copolymers in a high temperature solution process, the catalyst system comprising (i) a metallocene complex of formula (I) wherein M is Hf or Zr X is a sigma ligand, L is a bridge of the formula —SiR⁸₂—, wherein each R⁸ is independently a C₁-C₂₀-hydrocarbyl, tri(C₁-C₂₀-alkyl)silyl, C₆-C₂₀-aryl, C₇-C₂₀-arylalkyl or C₇-C₂₀-alkylaryl n is 0, 1 or 2 R¹ and R^1′ are the same or can be different and can be a linear or branched C₁-C₆-alkyl group, R² and R^2′ are the same or are different and are a CH₂—R⁹ group, with R⁹ being H or linear or branched C₁-C₆-alkyl group R⁵ and R^5′ are the same or are different and can be H or a linear or branched C₁-C₆-alkyl group or a OR group, wherein R is a C₁-C₆-alkyl group R⁶ and R^6′ are the same or are different and can be H or a C(R¹⁰)₃ group, with R¹⁰ being the same or different and R¹⁰ can be H or a linear or branched C₁-C₆-alkyl group or R⁵ and R⁶ and/or R^5′ and R^6′ taken together form an unsubstituted 4-7 membered ring condensed to the benzene ring of the indenyl moiety, with the proviso that if R⁵ and R⁶ as well as R^5′ and R^6′ taken together form an unsubstituted 5 membered ring condensed to the benzene ring of the indenyl moiety then R² and R^2′ are not a C₁-alkyl group; and R⁷ and R^7′ can be the same or are different and can be H or a linear or branched C₁-C₆-alkyl group (ii) an aluminoxane cocatalyst and (iii) optionally a boron containing cocatalyst

There are disclosed a transition metal compound of the general formula RMXa-1Lb (R is a pi ligand, a fused polycyclic cyclopentadienyl group in which at least one of many-membered rings to which cyclopentadienyl groups are fusedly bonded is a saturated ring, M is a transition metal, X is a sigma ligand, L is a Lewis base, a is the valency of M, and b is 0, 1 or 2); a polymerization catalyst for styrene, etc. comprising the above transition metal, preferably further comprising an oxygen atom containing compound ionic compound or organoboron compound and optionally a Lewis base; and a process for producing a polymer of a compound containing an ethylenically unsaturated double bond or an acetylenic polymer, especially a syndiotactic polystyrene by using the above polymerization catalyst. The catalyst is particularly effective for producing highly syndiotactic polystyrene minimized in residual metals amounts at a low cost in enhanced efficiency.

A new class of methylene-bridged metallocenes of formula (I), wherein M is a transition metal of group 3, 4, 5, 6, lanthanide or actinide; X is a monoanionic sigma ligand; R<1 >can be alkyl, cycloalkyl, aryl, alkylaryl or arylalkyl radicals; R<2 >can be halogen, alkyl, cycloalkyl, aryl, alkylaryl or arylalkyl radical; p is 0-3; m is 0-2; and n is 0-4. Furthermore, the corresponding ligands, a new process for their preparation and catalysts systems containing said methylene-bridged metallocenes are described.

A catalyst in solid particulate form free from an external carrier material comprising

• • (i) a complex of formula (I)

A complex of formula (I) wherein M is zirconium or hafnium; each X independently is a sigma ligand; L is a divalent bridge selected from —R′₂C—, —R′₂C—CR′₂—, —R′₂Si—, —R′₂Si—SiR′₂—, —R′₂Ge—, wherein each R′ is independently a hydrogen atom or a C₁-C₂₀-hydrocarbyl group optionally containing one or more silicon atoms or heteroatoms of Group 14-16 of the periodic table or fluorine atoms, and optionally two R′ groups taken together can form a ring; R² and R^2′ are each independently a C₁-C₂₀ hydrocarbyl group, —OC_1-hydrocarbyl group or —SC_1-20 hydrocarbyl group; R⁵ is a —OC_1-20 hydrocarbyl group or —SC_1-20 hydrocarbyl group, said R⁵ group being optionally substituted by one or more halo groups; R^5′ is hydrogen or a C_1-20 hydrocarbyl group; —OC_1-20 hydrocarbyl group or —SC_1-20 hydrocarbyl group; said C_1-20 hydrocarbyl group being optionally substituted by one or more halo groups; R⁶ and R^6′ are each independently a C_1-20 hydrocarbyl group; —C_1-20 hydrocarbyl group or —SC_1-20 hydrocarbyl group; each R¹ and R^1′ are independently —CH₂R^x wherein R^x are each independently H, or a C_1-20 hydrocarbyl group, optionally containing heteroatoms.

The invention refers to a combination comprising a sigma ligand of formula (I) and an opioid or opiate for use in the prevention and/or treatment of pain developed as a consequence of surgery, especially peripheral neuropathic pain, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuralgia, neuritis or neuropathy. The invention also refers to the sigma ligands of formula (I) for use in potentiating the analgesic effect of an opioid or opiate and/or for decreasing the dependency induced thereby when said opioid or opiate is used in the prevention and/or treatment of pain developed as a consequence of surgery.

The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferably SA-4503, or salts, or solvates thereof These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by ischemic stroke, diabetic peripheral neuropathy, cancer therapy induced neuropathy, multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, spinal cord injury, Huntington's disease or Parkinson's disease. In other methods, the sigma receptor ligands are administered after stroke to facilitate functional recovery. The administration of the sigma receptor ligands effects faster functional recovery.

Catalyst system for producing ethylene copolymers in a high temperature solution process, the catalyst system comprising (i) a metallocene complex of formula (I), M is Hf or a mixture with Zr, provided that more than 50% by moles of the complex of Formula I has M=Hf, X is a sigma ligand, R are the same or different from each other and can be saturated linear or branched C₁-C₁₀ alkyl, C₅-C₁₀ aryl, C₆-C₂₀ alkylaryl or C₆-C₂₀ arylalkyl groups, which can optionally contain up to 2 heteroatoms or silicon atoms, R¹ is a C₆-C₂₀-aryl, which can be unsubstituted or substituted by one or up to 5 linear or branched C₁-C₁₀ alkyl group(s), R² is a saturated linear or cyclic C₃-C₂₀ alkyl group or a branched CR³R⁴R⁵ group, wherein R³ is hydrogen or an C₁-C₂₀ alkyl group and R⁴ and R⁵ are the same or are different and can be an C₁-C₂₀ alkyl group and (ii) a boron containing cocatalyst

A catalyst comprising

• • (i) an asymmetric complex of formula (I)